Pfizer paid $650 million upfront to partner with Innovent Biologics on 12 early-stage cancer programs, a deal that’s worth up to $10.5 billion when milestones are included. The portfolio covers antibody-drug conjugates with novel differentiated payloads and multi-specific antibodies, all pre-Phase 2.
The Pfizer-Innovent collaboration divides the 12 programs into three tranches. Pfizer takes exclusive global rights to four, ex-China rights to four more, and co-develops the remaining four globally, co-commercializing those with Innovent in the U.S. and Europe. Innovent contributes eight early-stage assets; Pfizer puts in four discovery programs. Innovent runs Phase 1, then Pfizer leads global development.
Two weeks earlier, the BMS-Hengrui deal ran to $600 million upfront and up to $15.2 billion total across 13 programs. BMS contributes discovery assets and relies on Hengrui for Phase 1 speed. Two big Western oncology players have followed the same playbook inside two weeks.
What does Pfizer actually get for $650 million down? Access to China’s development system, which CEO Albert Bourla said at a TD Cowen event in March operates at “half the cost, three times the speed” of Western counterparts. He also flagged China’s “meteoric ascent” as one of two forces reshaping the industry. Every program is pre-Phase 2, and Pfizer’s paying to borrow a faster clock.
For Innovent, co-commercializing four programs in the U.S. and Europe is its stated five-year ambition made real.
Diana Kowalski